Perrillo R P
Gastroenterology Section, Veterans Administration Medical Center, St Louis, Missouri 63106.
Gut. 1993;34(2 Suppl):S95-6. doi: 10.1136/gut.34.2_suppl.s95.
This paper reviews the results of recent studies carried out in the USA on the treatment of chronic hepatitis B with interferon alfa-2b. In the US multicentre trial, 37% of patients lost hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV)-DNA when treated with 5 million units (MU) daily for 16 weeks, compared to 42% in the US National Institutes of Health (NIH) trial treated with 10 MU thrice weekly for 16 weeks. In both studies, the loss of HBeAg and HBV-DNA was associated with virological, biochemical, histological, and clinical improvement. Long term follow up in the National Institutes of Health study showed that 65% of responders had disappearance of HBsAg over a mean of four years, suggesting that termination of the HBV carrier state may be possible.
本文综述了美国近期开展的关于用α-2b干扰素治疗慢性乙型肝炎的研究结果。在美国多中心试验中，每日用500万单位（MU）治疗16周时，37%的患者乙肝e抗原（HBeAg）和乙肝病毒（HBV）-DNA转阴，而在美国国立卫生研究院（NIH）试验中，每周三次用10MU治疗16周时，这一比例为42%。在两项研究中，HBeAg和HBV-DNA转阴均与病毒学、生化、组织学及临床改善相关。国立卫生研究院研究的长期随访显示，65%的应答者在平均四年的时间里乙肝表面抗原（HBsAg）消失，提示可能终止HBV携带者状态。
